|
Diabetes Autoantibody Standardization Program (DASP)
|
Research Initiative
|
CDC
|
NIDDK
|
The aim of DASP is to improve the measurements of the autoantibodies predictive of type 1 diabetes, and to decrease laboratory-to-laboratory variation. In combination with genetic screening, autoantibody tests are used to identify individuals at elevated risk of developing type 1 diabetes and to characterize autoimmunity.
|
|
Diabetes Mellitus Interagency Coordinating Committee (DMICC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDCR, CSR, NCCAM, NCATS, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD
|
The DMICC facilitates cooperation, communication, and collaboration on diabetes among these government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate.
|
|
Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS)
|
Research Initiative
|
CDC, IHS
|
NIDDK, NCATS, NEI, NHLBI, NIA, NICHD, NIMHD, OD
|
The DPP showed that lifestyle change or metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP.
|
|
Diabetic Retinopathy Clinical Research Network
|
Research Initiative
|
OS
|
NEI, NIDDK
|
The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the NEI, and co-funded by OS, through NIDDK, with the Special Funding Program for Type 1 Diabetes Research.
|
|
Dietary Supplements Federal Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA, SAMHSA
|
NCCAM, NCI, NCATS, NHLBI, NIDDK, NIEHS
|
The ODS Federal Workgroup meets quarterly to review Guidelines for Dietary Supplements (botanics, probiotics/prebiotics; vitamins) reference standards. Collaborative initiatives, state of the science topics, conferences, and workshop are also discussed.
|
|
Dietary Supplements Ingredient Database (DSID)
|
Resource Development
|
CDC, FDA
|
OD, NCI
|
The database provides statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently the DSID provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Additional dietary supplement ingredients will be included in future releases of the database.
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
CC
|
Collaboration with M Choi, WC Cheng and A Badano from the Imaging Physics Lab, Divison of Imaging and Applied Mathematics Office of Science and Engineering Labs, CDRH, FDA. The project consists of developing software and establish validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis and therapy monitoring of marrow disorders.
|
|
Disconnected Youth and Gangs in the United States
|
Research Initiative
|
ACF
|
NICHD
|
This Inter-Agency Agreement (IAA) is to provide Fiscal Year 2011 funding to the NIH, NICHD for the award and management of one Phase 1 SBIR grant. The NICHD agrees to perform the grant award and management services for the Administration for Children and Families for this Phase 1 Small Business Innovation Research project entitled, "Disconnected Youth and Gangs in the United States".
|
|
Domestic Scheduling to Control New Drugs of Abuse, with NIDA-Funded Testing Conducted in Support of Drug Enforcement Administration (DEA) Scheduling Recommendations to the FDA
|
Research Initiative
|
FDA, OS
|
NIDA
|
HHS depends upon NIDA contracts to generate the in vitro and animal behavioral data that are required to support the domestic scheduling of new street drugs. The long-standing agreement is that DEA provides the drugs (or the funds to cover drug synthesis) to NIDA, and NIDA covers the cost of pharmacological testing.
|
|
Dominantly Inherited Alzheimer’s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset Dominantly Inherited Alzheimer’s Disease
|
Research Initiative
|
FDA
|
NIA
|
To set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered].
|